precisionmedicineonline54m
Despite Overall Survival Miss, Singapore Researchers Champion Success of Global Cell Therapy Trial
The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...
precisionmedicineonline5h
Children's Mercy Kansas City Brings Pharmacogenomic Testing In-House
The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...
precisionmedicineonline54m
European Commission Approves BeiGene's Tevimbra, Chemo in First-Line Gastric, Esophageal Cancers
The EC considered the treatment's activity in patients with advanced, PD-L1-positive esophageal and gastric cancers in the RATIONALE-305 and -306 trials.
precisionmedicineonline53m
Ataraxis AI Aims to Address Gaps in Molecular Testing with AI Digital Pathology Tests
The firm is engaging with regulators about its recently validated Ataraxis Breast test, which it hopes to make available for clinical use next year.
precisionmedicineonline3h
Anocca Seeking EMA Permission to Test TCR T-Cell Therapy in KRAS-Mutated Pancreatic Cancer
The Swedish firm plans to expand the VIDAR-1 umbrella trial to study additional KRAS-targeting product candidates in the future.
precisionmedicineonline4h
Sarepta Licenses Clinical, Preclinical siRNA Candidates From Arrowhead, Enters Discovery Deal
Sarepta will pay Arrowhead Pharmaceuticals $500 million upfront, make a $325 million equity investment, plus pay $250 million over five years, and more.